NovoCure Limited NVCR
11.81 USD -0.72 (-5.75%)
At closeNov 10, 2026, 4:01 PM EST
12.29 +0.48 +4.06%
After hours · Nov 10, 4:01 PM ET
11.56 Day range 12.95
9.82 52-week range 21.45
- YTD
- -8.66%
- 1 year
- +4.79%
- Market cap
- 1.38B
- Revenue (ttm)
- 725.39M
- Profit margin
- -16.78%
- EPS (ttm)
- -1.06
- Shares out
- 116.92M
- Forward P/E
- -16.23
- YTD return
- -8.66%
- 1-year return
- +4.79%
- Volume
- 1.93M
- Avg volume
- 1.48M
- Open
- 12.68
- Previous close
- 12.53
- Day's range
- 11.56 – 12.95
- 52-week range
- 9.82 – 21.45
- Beta
- 1.08
- Analysts
- Buy
- Price target
- 25.57 (+116.5%)
- Earnings date
- Feb 25, 2027
5D -2.34 (-16.49%)
Key statistics
- Enterprise value
- 1.23B
- PEG ratio
- 0.00
- Price / sales
- 1.90
- Price / book
- 3.79
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 15.70%
- Free cash flow
- 9.00M
- Total cash
- 463.48M
- Total debt
- 231.55M
- Return on equity
- -35.19%
- Short % of float
- 14.81%
- 50-day average
- 15.30
- 200-day average
- 14.81
Analyst view
Consensus: buy
Buy
Price target (mean) 25.57 +116.5% upside
Now 11.81
- Target (low)
- 15.00
- Target (mean)
- 25.57
- Target (high)
- 52.00
Ratings (0m) 7 4 buy · 3 hold · 0 sell
- Strong buy1
- Buy3
- Hold3
- Sell0
- Strong sell0
Next earnings
Feb 25, 2027
Expected Feb 25, 2027. Consensus EPS estimate -0.214.
Financials — quick view
NVCR Revenue — quarterly 193.40M
NVCR Net income — quarterly -10.44M
NVCR EPS — quarterly -0.09
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 25, 2027 | Dec 30, 2026 | -0.21 | — | — | — |
| Oct 29, 2026 | Sep 30, 2026 | -0.23487 | -0.09 | +0.14 | +61.68% |
| Jul 23, 2026 | Jun 30, 2026 | -0.33153 | -0.13 | +0.20 | +60.79% |
| Apr 30, 2026 | Mar 31, 2026 | -0.51219 | -0.62 | -0.11 | -21.05% |
| Feb 26, 2026 | Dec 31, 2025 | -0.41 | -0.22 | +0.19 | +46.34% |
| Oct 30, 2025 | Sep 30, 2025 | -0.42 | -0.33 | +0.09 | +21.43% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 10, 2026 | Wedbush | main | Neutral | Neutral |
| Oct 30, 2026 | Wells Fargo | main | Equal-Weight | Equal-Weight |
| Oct 30, 2026 | Evercore ISI Group | main | Outperform | Outperform |
| Jul 24, 2026 | Wedbush | main | Neutral | Neutral |
| Jul 23, 2026 | HC Wainwright & Co. | main | Buy | Buy |
| Jun 18, 2026 | HC Wainwright & Co. | reit | Buy | Buy |
About NovoCure Limited
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. Its TTFields devices include Optune Gio, Optune Lua, and Optune Pax. The company also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Baar, Switzerland.
- Sector
- Healthcare
- Industry
- Medical Devices
- Country
- Switzerland
- Website
- novocure.com
News
12 Health Care Stocks Moving In Tuesday's After-Market Session 
FDA Rejects NovoCure's Optune Mya for Lung Cancer Brain Metastases. Here's What It Means for Investors. 
Wedbush Maintains Neutral on NovoCure, Lowers Price Target to $19 
Novocure Stock Slips After FDA Rejects Its Cancer Treatment Device - Novocure Receives Not Approvable Letter From FDA In Response To PMA Application For Optune Mya For Treatment Of Adult Patients With Brain Metastases From Non-Small Cell Lung Cancer Following Stereotactic Radiation
Wells Fargo Maintains Equal-Weight on NovoCure, Lowers Price Target to $15 
Evercore ISI Group Maintains Outperform on NovoCure, Lowers Price Target to $20 
NovoCure Q3 2026 Earnings Call Transcript - NovoCure Q3 EPS $(0.09) Beats $(0.24) Estimate, Sales $193.399M Beat $182.233M Estimate
NovoCure Raises FY2026 Sales Guidance from $710.000M-$725.000M to $736.000M-$743.000M vs $725.814M Est
Your note
Sign in to keep a note on NVCR — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BEN ARYE BARAK | General Counsel | Stock Award(Grant) | Jun 29, 2026 | 243,752 |
| BRACKMANN CHRISTOPH | Chief Financial Officer | Sale | Mar 3, 2026 | 182,842 |
| CORDOVA ASHLEY | Former | Stock Award(Grant) | Feb 26, 2026 | 440,208 |
| DANZIGER ASAF | Director | Stock Award(Grant) | Jun 29, 2026 | 416,742 |
| DOYLE WILLIAM F | Officer and Director | Stock Award(Grant) | Mar 2, 2026 | 328,397 |
| LEONARD FRANCIS XAVIER II | Chief Executive Officer | Stock Award(Grant) | Jun 29, 2026 | 461,425 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| FMR, LLC | 14.86% | 17,373,078 | 205.18M | Jun 29, 2026 |
| Blackrock Inc. | 11.47% | 13,413,699 | 158.42M | Jun 29, 2026 |
| Soleus Capital Management, L.P. | 8.48% | 9,913,401 | 117.08M | Jun 29, 2026 |
| Vanguard Portfolio Management LLC | 5.36% | 6,272,490 | 74.08M | Jun 29, 2026 |
| Vanguard Capital Management LLC | 4.19% | 4,903,633 | 57.91M | Jun 29, 2026 |
| Morgan Stanley | 3.87% | 4,522,389 | 53.41M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund | 5.02% | 5,874,496 | 69.38M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.99% | 3,490,920 | 41.23M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.36% | 2,762,752 | 32.63M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 2.16% | 2,521,417 | 29.78M | Jun 29, 2026 |
| Fidelity Mt. Vernon Street Trust-Fidelity Growth Company K6 Fund | 1.49% | 1,741,745 | 20.57M | Sep 29, 2026 |
| Fidelity Mt. Vernon Street Trust-Fidelity Series Growth Company Fund | 1.33% | 1,550,900 | 18.32M | Sep 29, 2026 |